BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21368672)

  • 21. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
    Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
    J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
    Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
    Appel IM; Hop WC; Pieters R
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients.
    Avramis VI; Spence SA
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):239-47. PubMed ID: 17414566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
    Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
    Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
    Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic panniculitis caused by L-asparaginase induced acute pancreatitis in a child with acute lymphoblastic leukemia.
    Chiewchengchol D; Wananukul S; Noppakun N
    Pediatr Dermatol; 2009; 26(1):47-9. PubMed ID: 19250405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
    Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
    Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
    Albertsen BK; Schrøder H; Jakobsen P; Avramis VI; Müller HJ; Schmiegelow K; Carlsen NT
    Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
    Rodriguez T; Baumgarten E; Fengler R; Soumpasis D; Henze G
    Klin Padiatr; 1995; 207(4):207-10. PubMed ID: 7564153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
    Wacker P; Land VJ; Camitta BM; Kurtzberg J; Pullen J; Harris MB; Shuster JJ;
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):627-32. PubMed ID: 17805038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
    Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
    Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
    Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
    Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.
    Wu SF; Chen AC; Peng CT; Wu KH
    Pediatr Blood Cancer; 2008 Dec; 51(6):824-5. PubMed ID: 18726919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
    Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
    Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
    Malbora B; Avci Z; Ozbek N
    Drug Chem Toxicol; 2012 Oct; 35(4):463-6. PubMed ID: 22149271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.